Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc. for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023.
Featured Posts
After nearly three years, the COVID-19 research collaboration between Vir Biotechnology and GSK has largely come to an end, as Vir announced Monday it would be going it alone or with other partners in this space.
The bankruptcy case filed by Johnson & Johnson’s subsidiary shouldering talc-related lawsuits will soon be dismissed unless a U.S appeals court agrees to reconsider its decision to nix the company’s attempt to offload the litigation into Chapter 11 proceedings, a federal judge said on Tuesday.
The World Health Organization is increasing its epidemiological surveillance in Equatorial Guinea after the country confirmed its first outbreak of the Marburg virus, a WHO official said on Tuesday.
Vivek Ramaswamy, the founder of Roivant Sciences, is considering a bid for the Republican presidential nomination, according to a report by POLITICO Monday.
Fresh off of his Sanofi exit, John Reed is joining Johnson & Johnson, where he will serve as executive vice president, pharmaceuticals, R&D, the New Jersey-based company announced late Monday afternoon.
As oncology drugs receive accelerated approvals, payers are questioning whether the benefits of these products outweigh the cost, spurring manufacturers to explore value-based agreements.
As COVID ripped across China and filled emergency wards, privileged patients cut hospital queues because they knew someone, offered a bribe or paid people with connections, said three people who accessed care through such means and seven doctors in six cities.
Over the past decade, mobile devices, sensors, and wearables have become more common in clinical trials, improving patient-centricity and accessibility. However, despite improving patient recruitment, retention, and satisfaction in research, these innovations have also imposed an increased burden on on-site staff – as well as patients.
Consolidation is driven by larger pharma companies snapping up smaller players to access new therapies recently approved by the FDA or in clinical development. In addition, Private equity firms are taking a stake in ownership while also funding biotech and emerging pharmaceutical companies.